Table 12Fluoxetine compared with placebo

Domains pertaining to strength of evidenceMagnitude of effectStrength of evidence
Number of studies; number of subjectsRisk of bias (design/quality)ConsistencyDirectnessPrecisionSummary effect size (95% confidence interval)High, Moderate, Low, Insufficient
Pain: Mean change in visual analogue scale
1; N=51RCT/FairNAIndirectPrecise−29% vs. −7%, P=0.002Insufficient
Fibromyalgia Impact Questionnaire Total Score
1; N=51RCT/FairNAIndirectPrecise−20% vs. +7%, P=0.005Insufficient
1; N=51RCT/FairNAIndirectPrecise−16% vs. +4%, P=0.05Insufficient
50% response, overall adverse events, withdrawals due to adverse events
No dataNANANANANAInsufficient

From: Appendix F, Strength of evidence

Cover of Drug Class Review: Drugs for Fibromyalgia
Drug Class Review: Drugs for Fibromyalgia: Final Original Report [Internet].
Smith B, Peterson K, Fu R, et al.
Portland (OR): Oregon Health & Science University; 2011 Apr.
Copyright © 2011, Oregon Health & Science University.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.